Top Markets
Coin of the day
Mithra Pharmaceuticals S.A. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITRA
Rang in Aktien #30361
Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège,... Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.
Aktienkurs
$0.25620952
Zuletzt synchronisiert: 2024-07-23
Marktkapitalisierung
$17.14M
Veränderung (1 Tag)
10.83%
Veränderung (1 Jahr)
0.00%
Land
BE
Handel Mithra Pharmaceuticals S.A. (MITRA)

Kategorie

EPS für Mithra Pharmaceuticals S.A. (MITRA)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Mithra Pharmaceuticals S.A. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Mithra Pharmaceuticals S.A. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber